AITRICS, a medical AI company specializing in biosignal-based solutions, has raised KRW 35 billion in its Series C funding round, bringing its total accumulated investment to KRW 73.1 billion. The round was led by existing investors including Premier Partners, Han River Partners, Mirae Asset Venture Investment, and Shinyoung Securities-BSK Investment, alongside new investors KB Securities-Solidus Investment, SV Investment, and Mirae Asset Capital.
AITRICS plans to use this investment to strengthen its core solutions and expand globally. The company will enhance the functionality of AITRICS-VC (VitalCare), its solution for predicting patient deterioration, and V.Doc Pro, its AI copilot solution for medical staff, while also reinforcing research and development for new pipelines.
The company is also launching full-scale overseas operations. Centered around its local subsidiaries in the U.S. and Japan, AITRICS plans to expand its business into Asian regions such as Vietnam and Hong Kong. Additionally, through collaboration with the Mayo Clinic Platform, the company aims to accelerate model development validation and global market expansion.
